910486-72-5

Basic information

• Product Name: 6-Chloro-2-ethylpyridin-3-aMine
• Synonyms: 6-Chloro-2-ethylpyridin-3-aMine
• CAS NO: 910486-72-5
• Molecular Formula: C7H9ClN2
• Molecular Weight: 156.61276
• Mol File: 910486-72-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-Chloro-2-ethylpyridin-3-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-2-ethylpyridin-3-aMine(910486-72-5)
• EPA Substance Registry System: 6-Chloro-2-ethylpyridin-3-aMine(910486-72-5)

Safety Data

• Hazardous Substances Data: 910486-72-5(Hazardous Substances Data)

Usage

General Description

6-Chloro-2-ethylpyridin-3-amine is a chemical compound with the molecular formula C8H10ClN. It is a derivative of pyridine and belongs to the class of amines. This chemical compound is characterized by the presence of a chlorine atom at the 6th position, an ethyl group at the 2nd position, and an amine group at the 3rd position of the pyridine ring. It is commonly used as an intermediate in the synthesis of pharmaceutical products and agrochemicals. Additionally, it has potential applications in research and development, as well as in the manufacturing of various organic compounds.

Upstream product

• 62476-56-6 3-amino-2,6-dichloropyridine 
• 97-93-8 triethylaluminum 

Downstream Products

• 864775-64-4 5-chloro-3-methyl-1H-pyrazolo[4,3-b]pyridine 

Relevant articles and documents

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening

The mediator complex-associated cyclin dependent kinase CDK8 regulates β-catenin-dependent transcription following activation of WNT signaling. Multiple lines of evidence suggest CDK8 may act as an oncogene in the development of colorectal cancer. Here we describe the successful optimization of an imidazo-thiadiazole series of CDK8 inhibitors that was identified in a high-throughput screening campaign and further progressed by structure-based design. In several optimization cycles, we improved the microsomal stability, potency, and kinase selectivity. The initial imidazo-thiadiazole scaffold was replaced by a 3-methyl-1H-pyrazolo[3,4-b]-pyridine which resulted in compound 25 (MSC2530818) that displayed excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable. Furthermore, we demonstrated modulation of phospho-STAT1, a pharmacodynamic biomarker of CDK8 activity, and tumor growth inhibition in an APC mutant SW620 human colorectal carcinoma xenograft model after oral administration. Compound 25 demonstrated suitable potency and selectivity to progress into preclinical in vivo efficacy and safety studies.